Sabatini Brent 4

What Happened
Brent Sabatini, SVP and Chief Accounting Officer at Vir Biotechnology, sold 379 shares of VIR common stock on June 1, 2026. The shares were disposed at $9.45 per share for a total transaction value of $3,582. The sale was executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date and price: 2026-06-01 — 379 shares at $9.45/share (total $3,582).
• Transaction type/code: Sale (S) — open market or private sale.
• Filing/timeliness: Report filed 2026-06-02 for a 2026-06-01 transaction (not flagged as late).
• Shares owned after transaction: Not specified in the Form 4.
• Footnotes: F1 — sale effected pursuant to a 10b5-1 plan adopted Dec 19, 2025. F2 — the 379 shares were acquired May 29, 2026 under an employee stock purchase program (ESPP).

Context
A sale under a Rule 10b5-1 plan typically reflects a prearranged disposition and is often routine rather than an immediate signal about company prospects. The dollar value here ($3.6k) is small, so this single transaction is unlikely to be material for most investors.